Related Experiment Videos
Patients with localized non-Hodgkin's lymphomas provide opportunities for future research
1University of Arizona, Tucson.
Abstract:
Over the past 15 years, we have learned that apparently localized non-Hodgkin's lymphomas of aggressive histologic subtypes are often microscopically disseminated diseases at the time of diagnosis, requiring systemic chemotherapy with doxorubicin-containing regimens to maximize the possibility of cure. This strategy results in cures for approximately 95% of stage I patients and 75% of stage II patients. There may be some additional benefit of consolidative radiotherapy following initial chemotherapy. In spite of these accomplishments, up to 30% of patients still fail treatment and die. We are currently unable to identify these patients prior to treatment, and additional empiric changes in the chemotherapy regimens are unlikely to further improve survival. Therefore, we need continued research aimed at increased understanding of the biology of non-Hodgkin's lymphomas.
Insights
Aggressive non-Hodgkin's lymphomas are often widespread at diagnosis, requiring chemotherapy for cure. Despite treatment advances, some patients still die, highlighting the need for further biological research.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Aggressive non-Hodgkin's lymphomas (NHLs) are frequently diagnosed as microscopically disseminated diseases.
- Current treatment involves systemic chemotherapy, often with doxorubicin-containing regimens, to achieve cures.
Purpose of the Study:
- To review treatment outcomes for aggressive non-Hodgkin's lymphomas.
- To identify limitations in current treatment strategies and highlight the need for further research.
Main Methods:
- Review of treatment data and outcomes over the past 15 years for aggressive non-Hodgkin's lymphomas.
- Analysis of cure rates for different stages and the impact of consolidative radiotherapy.
Main Results:
- Chemotherapy achieves high cure rates for Stage I (95%) and Stage II (75%) aggressive NHL.
- Consolidative radiotherapy may offer additional benefit after chemotherapy.
- Up to 30% of patients experience treatment failure and mortality.
Conclusions:
- Current systemic chemotherapy regimens are effective but cannot cure all patients with aggressive NHL.
- Identifying patients likely to fail treatment before it begins remains a challenge.
- Further research into the underlying biology of non-Hodgkin's lymphomas is crucial for improving survival.